EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Baxalta's enterprise value is $30,917 Mil.
Baxalta's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was $1,360 Mil. Therefore, Baxalta's EV-to-EBITDA for today is 22.73.
The historical rank and industry rank for Baxalta's EV-to-EBITDA or its related term are showing as below:
BXLT's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.535 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-06), Baxalta's stock price is $46.02.
Baxalta's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $1.208. Therefore, Baxalta's PE Ratio for today is 38.10.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Baxalta EV-to-EBITDA Historical Data
The historical data trend for Baxalta's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Baxalta's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxalta's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Baxalta's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Baxalta's EV-to-EBITDA falls into.
Baxalta EV-to-EBITDA Calculation
Baxalta's EV-to-EBITDA for today is calculated as:
Baxalta's current Enterprise Value is $30,917 Mil.
Baxalta's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,360 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxalta (NYSE:BXLT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Baxalta's share price for today is $46.02.
Baxalta's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.208.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Baxalta's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BXLT has been successfully added to your 